AMENDED AND RESTATED UNIT PURCHASE AGREEMENT BY AND AMONG RELMADA THERAPEUTICS, INC. AND EACH PURCHASER IDENTIFIED ON APPENDIX A HERETOUnit Purchase Agreement • December 3rd, 2019 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED UNIT PURCHASE AGREEMENT (this “Agreement”) entered into as of November 27, 2019, and effective as of February 12, 2019, by and among Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on Appendix A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”) amends and restates in its entirety the Unit Purchase Agreement among the parties hereto dated as of February 12, 2019.
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • December 3rd, 2019 • Relmada Therapeutics, Inc. • Pharmaceutical preparations • New York
This Amendment No. 1 to License Agreement (this “Amendment”), dated as of December 2, 2019, is made by and between Relmada Therapeutics, Inc., a Nevada corporation (“Licensee”) and Dr. Charles E. Inturrisi, an individual, and Dr. Paolo Manfredi, an individual, jointly and severally (collectively, “Licensor”).
